Skip to content

Application of Tigecycline Fumarate Combined with Transversus Abdominis Plane Block in Multimodal Analgesia for Patients Undergoing Laparoscopic Gastrointestinal Tumor Surgery:A prospective Cohort Study

Application of Tigecycline Fumarate Combined with Transversus Abdominis Plane Block in Multimodal Analgesia for Patients Undergoing Laparoscopic Gastrointestinal Tumor Surgery:A prospective Cohort Study

Status
Recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500112722
Enrollment
Unknown
Registered
2025-11-19
Start date
2025-11-19
Completion date
Unknown
Last updated
2025-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gastrointestinal

Interventions

PCIA0.075mg/kg:Postoperative PCIA analgesia 0.075mg/kg
T3 group:A patient-controlled analgesia (PCA) regimen with no background infusion and a 3-mL bolus dose

Sponsors

The First Affiliated Hospital of University of Science and Technology of China West (Anhui Provincial Cancer Hospital)
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. patients undergoing laparoscopic gastrointestinal oncological surgery with American Society of Anaesthesiologists (ASA) classification II-III were to be included. 2. Age range: 18 years old = 4. 5. The patient or his/her family can understand the study, voluntarily sign the informed consent form, and are willing to comply with the requirements of the trial protocol.

Exclusion criteria

Exclusion criteria: 1. Those who are allergic or contraindicated to benzodiazepines, opioids, cypropofol, flumazenil, naloxone, tegretol fumarate and other drugs and their drug components. 2. Severe cardiac, pulmonary and renal insufficiency, combined with a variety of chronic diseases can not tolerate surgical anaesthesia. 3. Those with a history of alcoholism, opioid allergy or a history of abuse of such drugs. 4. Other conditions that the investigator considers unsuitable for enrolment. 5. Patients with recent neurological diseases or surgery.

Design outcomes

Primary

MeasureTime frame
Difference in resting/motor pain intensity within 24 hours after surgery;

Secondary

MeasureTime frame
First time to remedy analgesia;Total opioid consumption;Postoperative recovery indicators;Security indicators;

Countries

China

Contacts

Public ContactChaoliang Tang

The First Affiliated Hospital Of USTC

chaolt@ustc.edu.cn+86 138 6677 7142

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026